Nebulized Tyvaso Enters FDA Review for Idiopathic Pulmonary Fibrosis, with a Decision Expected in Late April 2027
The FDA accepted United Therapeutics' application for nebulized Tyvaso in IPF, with a decision expected in late April 2027. What patients should know now.
Medical Daily ·